Why Boston's Biotech Talent Is Moving to California: A Shift in Innovation Hubs

Boston's prestigious institutions like Harvard and MIT have long been epicenters of biotech innovation, yet rising costs, high taxes, and challenging business conditions are driving entrepreneurs to establish startups elsewhere, particularly in California. This migration reflects a broader trend affecting the U.S. biotech landscape, where operational expenses and regulatory environment significantly impact where companies choose to develop new treatments and medical breakthroughs. The shift has implications for patients' access to emerging therapies, as the concentration of biotech resources in different regions may affect research timelines and funding availability for developing new drugs and medical solutions.